News

Based on the results of pre-clinical and clinical trials conducted by SanBio, Teijin plans to begin clinical trials in Japan. SanBio developed SB623 by processing bone marrow from

The orphan drug designation potentially may provide AVI up to ten years of market exclusivity, if the drug candidate is approved for marketing in the EU. AVI-4658, another

Preliminary clinical data from the first 24 weeks of the study (12 weeks at 0.1mg/kg and 12 weeks at 1.0mg/kg) have been evaluated. BioMarin plans to announce top-line

The Qiagen assay is designed to identify those patients whose tumors express the EGFRvIII mutation, allowing for the possibility of more targeted and personalised treatment. The company said

Currently, the most widely-used treatment for type 1 diabetes is the regular injection of insulin, a burdensome task for patients. Islet cell transplantation, whereby insulin-producing cells from a

The new drug application (NDA) for Zuplenz was accepted for review by the FDA in June 2009, and a response is expected in the first quarter of 2010

The company said that StarDrop 4.3 is the first major update to StarDrop, helping scientists to select high quality drug candidates thereby improving efficiency and productivity. StarDrop 4.3

The company said that the new SensiGene Fetal RhD Genotyping test is designed to detect circulating cell-free fetal (ccff) DNA from maternal blood and examine multiple regions of

Reported sales in the quarter increased 15% to $12.5 billion, compared to reported sales in the same period last year. EBITDA on a pro forma basis, excluding certain